Abstract: Provided are structures and methods for forming structures with sloping surfaces of a desired profile. An exemplary method includes performing a first etch process to differentially etch a gate material to a recessed surface, wherein the recessed surface includes a first horn at a first edge, a second horn at a second edge, and a valley located between the first horn and the second horn; depositing an etch-retarding layer over the recessed surface, wherein the etch-retarding layer has a central region over the valley and has edge regions over the horns, and wherein the central region of the etch-retarding layer is thicker than the edge regions of the etch-retarding layer; and performing a second etch process to recess the horns to establish the gate material with a desired profile.

Abstract: A semiconductor device is disclosed. The semiconductor device includes a semiconductor fin. The semiconductor device includes first spacers over the semiconductor fin. The semiconductor device includes a metal gate structure, over the semiconductor fin, that is sandwiched at least by the first spacers. The semiconductor device includes a gate electrode contacting the metal gate structure. An interface between the metal gate structure and the gate electrode has its side portions extending toward the semiconductor fin with a first distance and a central portion extending toward the semiconductor fin with a second distance, the first distance being substantially less than the second distance.

Abstract: Disclosures of the present invention describe a method of treatment of preventing hyperglycemia complications using at least one pharmaceutical made from a red mold product, wherein the red mold product is a red mold rice or a red mold Dioscorea, and the pharmaceutical is an extract obtained from the red mold product. Particularly, the extract can be Monascin, Ankaflavin, or a combination of Monascin and Ankaflavin. Moreover, a variety of experiment data have proved that the extract indeed exhibits a prevention effect in hyperglycemia complications comprising non-alcoholic liver damage and kidney failure.

Abstract: Disclosures of the present invention describe a method of treatment of preventing hyperglycemia complications using at least one pharmaceutical made from a red mold product, wherein the red mold product is a red mold rice or a red mold Dioscorea, and the pharmaceutical is an extract obtained from the red mold product. Particularly, the extract can be Monascin, Ankaflavin, or a combination of Monascin and Ankaflavin. Moreover, a variety of experiment data have proved that the extract indeed exhibits a prevention effect in hyperglycemia complications comprising non-alcoholic liver damage and kidney failure.

Abstract: The present invention provides a composition for regulating blood sugar. The composition comprises at least one yellow pigment extracted from a red mold product, wherein the said yellow pigment is Monascin, Ankaflavin, or combination of Monascin and Ankaflavin. Moreover, results of a variety of animal experiments have proved that this blood sugar regulating composition indeed possess the functionalities of: lowering Hyperglycemia induced by high energy diet, alleviating ROS and inflammatory caused by the Hyperglycemia, reduce AST and ALT value of liver as well as sarcosine value of kidney.

Abstract: The present invention provides a novel pure substance extracting method. Differing from conventional pure substance extracting method utilizing chromatography technique to treat a red mold product with an extracting and purifying process by using a plurality of organic extracting solution, the present invention merely utilizes water and ethanol solution to extract the pure substances of Monascin and Ankaflavin from the red mold product. Based on experimental results, the precipitate of the substances obtained through this novel extracting method is able to contain high extraction ratio of Monascin (˜97.35%) and Ankaflavin (˜95.16%). Moreover, experimental results also prove that the novel pure substance extracting method includes the advantages of high extraction speed, high extraction efficiency, high extraction percentage, and using single organic solution.

Abstract: The present invention provides a composition for alleviating and preventing Alzheimer's disease. This composition comprises at least one yellow pigment extracted from a red mold product, and the said yellow pigment is Monascin or Ankaflavin. Moreover, after completing a variety of experiments, the composition has been proved possessing effects on alleviating and preventing AD by alleviating the symptoms of memory loss and learning disability resulted from the ?-amyloid accumulated in brain of rats as well as reducing the inflammation and the oxidative stress caused by the ?-amyloid in cerebral cortex and hippocampus tissue. Therefore, the experimental results have proved that this novel composition is indeed able to treat and prevent Alzheimer's disease.

Abstract: The present invention relates to a lactobacillus mutant, a nucleotide sequence for lactobacillus mutant, and primers for nucleotide sequence of lactobacillus mutant. The lactobacillus mutant is Lactobacillus paracasei subsp. paracasei NTU 101 having the nucleotide sequence of SEQ ID NO 1, and deposited with Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH (DSMZ, Germany) on Nov. 18, 2013, wherein the accession number of Lactobacillus paracasei subsp. paracasei NTU 101 is DSM 28047. Moreover, a nucleotide sequence for NTU 101 and the primers for the nucleotide sequence are also proposed for facilitating the person skilled in Lactobacillus filed capable of carrying out the strain identification of the NTU 101 according to the present invention. Moreover, the person skilled in Lactobacillus filed can also rapidly complete the strain identification of the NTU 101 by using DNA molecular marker technology, without culturing any isolated Lactobacillus strain or live Lactobacillus bacteria.

Abstract: The present invention discloses a composition for lowering blood lipid and elevating high-density lipoprotein and a method for manufacturing the same; the composition comprises monascin or ankaflavin, or a combination thereof; the manufacturing method comprises the steps of: treating a Monascus fermented product with acetone for three times; elevating the concentration of the Monascus fermented product by a process of decompress concentration; and extracting the monascin and the ankaflavin from the Monascus fermented product with a silica gel column chromatography, a Sephadex LH-20 column chromatography, the silica gel column chromatography, and a preparative high performance liquid chromatography sequentially.

Abstract: The present invention discloses a composition for lowering blood lipid and elevating high-density lipoprotein and a method for manufacturing the same; the composition comprises monascin or ankaflavin, or a combination thereof; the manufacturing method comprises the steps of: treating a Monascus fermented product with acetone for three times; elevating the concentration of the Monascus fermented product by a process of decompress concentration; and extracting the monascin and the ankaflavin from the Monascus fermented product with a silica gel column chromatography, a Sephadex LH-20 column chromatography, the silica gel column chromatography, and a preparative high performance liquid chromatography sequentially.

Abstract: The present invention relates to a mutant of Monascus purpureus NTU 568, a nucleotide sequence for Monascus purpureus NTU 568 and primers for nucleotide sequence of Monascus purpureus NTU 568, wherein the Monascus purpureus NTU 568 having the nucleotide sequence of SEQ ID NO 1, SEQ ID NO 2 or SEQ ID NO 3 is deposited with Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH (DSMZ, Inhoffenstr. 7B, D-38124 Braunschweig, Germany) on Nov. 18, 2013, with the accession number of DSM 28072. Moreover, the nucleotide sequence for NTU 568 and the primers for the nucleotide sequence are proposed in order to facilitate the person skilled in Monascus purpureus filed capable of carrying out the strain (mutant) identification of the NTU 568 according to the present invention.

Abstract: The present invention relates to a lactobacillus mutant, a nucleotide sequence for lactobacillus mutant, and primers for nucleotide sequence of lactobacillus mutant. The lactobacillus mutant is Lactobacillus paracasei subsp. paracasei NTU 101 having the nucleotide sequence of SEQ ID NO 1, and deposited with Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH (DSMZ, Inhoffenstr. 7B, D-38124 Braunschweig, Germany) on Nov. 18, 2013, wherein the accession number of Lactobacillus paracasei subsp. paracasei NTU 101 is DSM 28047. In the present invention, a nucleotide sequence for NTU 101 and the primers for the nucleotide sequence are proposed in order to facilitate the person skilled in Lactobacillus filed capable of carrying out the strain (mutant) identification of the NTU 101 according to the present invention.

Abstract: The present invention relates to a blood pressure reducing composition and primers for Monascus purpureus NTU 568, wherein the composition is a red mold dioscorea (RMD) manufacturing by way of inoculating a Monascus purpureus NTU 568 to a dioscorea substrate and then treating the inoculated dioscorea with culturing and drying processes. This composition is able to reduce blood pressure and prevent the vascular wall from pathological deterioration; therefore, the composition can be applied to clinical treatment and health food. Moreover, at least one nucleotide sequence for M. purpureus NTU 568 and the primers for the nucleotide sequence are also provided in the present invention in order to facilitate the person skilled in Monascus purpureus related art capable of accomplishing the strain (mutant) identification of the M. purpureus NTU 568.

Abstract: The present invention relates to a lactobacillus mutant, a nucleotide sequence for lactobacillus mutant, and primers for nucleotide sequence of lactobacillus mutant. The lactobacillus mutant is Lactobacillus paracasei subsp. paracasei NTU 101 having the nucleotide sequence of SEQ ID NO 1, and deposited with Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH (DSMZ, Germany) on Nov. 18, 2013, wherein the accession number of Lactobacillus paracasei subsp. paracasei NTU 101 is DSM 28047. Moreover, a nucleotide sequence for NTU 101 and the primers for the nucleotide sequence are also proposed for facilitating the person skilled in Lactobacillus filed capable of carrying out the strain identification of the NTU 101 according to the present invention. Moreover, the person skilled in Lactobacillus filed can also rapidly complete the strain identification of the NTU 101 by using DNA molecular marker technology, without culturing any isolated Lactobacillus strain or live Lactobacillus bacteria.

Abstract: The present invention relates to a mutant of Monascus purpureus NTU 568, a nucleotide sequence for Monascus purpureus NTU 568 and primers for nucleotide sequence of Monascus purpureus NTU 568, wherein the Monascus purpureus NTU 568 having the nucleotide sequence of SEQ ID NO 1, SEQ ID NO 2 or SEQ ID NO 3 is deposited with Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH (DSMZ, Inhoffenstr. 7B, D-38124 Braunschweig, Germany) on Nov. 18, 2013, with the accession number of DSM 28072. Moreover, the nucleotide sequence for NTU 568 and the primers for the nucleotide sequence are proposed in order to facilitate the person skilled in Monascus purpureus filed capable of carrying out the strain (mutant) identification of the NTU 568 according to the present invention.

Abstract: The present invention relates to a lactobacillus mutant, a nucleotide sequence for lactobacillus mutant, and primers for nucleotide sequence of lactobacillus mutant. The lactobacillus mutant is Lactobacillus paracasei subsp. paracasei NTU 101 having the nucleotide sequence of SEQ ID NO 1, and deposited with Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH (DSMZ, Inhoffenstr. 7B, D-38124 Braunschweig, Germany) on Nov. 18, 2013, wherein the accession number of Lactobacillus paracasei subsp. paracasei NTU 101 is DSM 28047. In the present invention, a nucleotide sequence for NTU 101 and the primers for the nucleotide sequence are proposed in order to facilitate the person skilled in Lactobacillus filed capable of carrying out the strain (mutant) identification of the NTU 101 according to the present invention.

Abstract: The present invention discloses a method for manufacturing red mold dioscorea, and the method comprises the following steps: washing and cutting a fresh dioscorea into pieces with a specific dimension; drying the pieces of the fresh dioscorea for making the dried dioscorea contain a specific water content and a specific sulfur content; adding some water with an appropriate ratio to fresh dioscorea or dried dioscorea; sterilizing the dioscorea; after the dioscorea being cooled down, inoculating the dioscorea with Monascus species; cultivating the dioscorea with an appropriate temperature, an appropriate humidity and an appropriate shacking frequency for an appropriate time period; and drying the cultivated red mold dioscorea with an appropriate water content.

Abstract: The present invention discloses a method for manufacturing red mold dioscorea, and the method comprises the following steps: washing and cutting a fresh dioscorea into pieces with a specific dimension; drying the pieces of the fresh dioscorea for making the dried dioscorea contain a specific water content and a specific sulfur content; adding some water with an appropriate ratio to fresh dioscorea or dried dioscorea; sterilizing the dioscorea; after the dioscorea being cooled down, inoculating the dioscorea with Monascus species; cultivating the dioscorea with an appropriate temperature, an appropriate humidity and an appropriate shacking frequency for an appropriate time period; and drying the cultivated red mold dioscorea with an appropriate water content.

Abstract: The present invention discloses a method for manufacturing red mold dioscorea, and the method comprises the following steps: washing and cutting a fresh dioscorea into pieces with a specific dimension; drying the pieces of the fresh dioscorea for making the dried dioscorea contain a specific water content and a specific sulfur content; adding some water with an appropriate ratio to fresh dioscorea or dried dioscorea; sterilizing the dioscorea; after the dioscorea being cooled down, inoculating the dioscorea with Monascus species; cultivating the dioscorea with an appropriate temperature, an appropriate humidity and an appropriate shacking frequency for an appropriate time period; and drying the cultivated red mold dioscorea with an appropriate water content.

Abstract: The present invention relates to a soymilk with additive of vitamin C, vitamin C salts or vitamin C stereoisomer, wherein the soymilk with vitamin C additive is made by adding an ascorbic acid into a drink fabricated by using at least one kind of bean as the raw material, and the soymilk with vitamin C additive is helpful to increase the iron absorptivity in small intestine, the additive dosage of the ascorbic acid is ranged from 25 mg/100 ml to 50 mg/100 ml. Moreover, the equivalent dosage of the ascorbate ion provided by the ascorbate or ascorbic acid stereoisomer is also ranged from 25 mg/100 ml to 50 mg/100 ml.